RIBOXX PHARMACEUTICALS Announce an Exclusive License Agreement

RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and TOLLYS SAS, a biotech company developing new therapeutic strategies in cancer, announced that they have signed a license agreement that grants TOLLYS exclusive global development and commercialization rights to a new drug development program, which RIBOXX will refer to as APOXXIM®. Under the terms of the license agreement, TOLLYS will assume sole responsibility for global development and commercialization of APOXXIM® product candidate. Riboxx will be responsible for manufacturing and supply of APOXXIM® to TOLLYS.

APOXXIM® is a Toll-like Receptor 3 (TLR3)-ligand that eliminates cancer cells by activating the TLR3 pathway. APOXXIM® displays unique physico-chemical and biological properties, as well as optimal Bioavailability with increased stability to degradation in body fluids such as human plasma. APOXXIM® is manufactured with the unique patented cGMP TENPORA®-Process of Riboxx.

Jacques Rohayem, CEO and CSO of RIBOXX PHARMACEUTICALS declared: "We are very thrilled to start this collaboration with TOLLYS, a company with a very strong scientific expertise in cancer therapy. This collaboration expands the portfolio of Riboxx drug development programs such as RIBOXXIM®, RIBOXXOL® and QUADROXXIM®, mainly focusing on cancer immunotherapy."

Jacques-François Martin, President of TOLLYS declared: "TOLLYS is very pleased to start this collaboration towards the development of a new and unique therapeutic strategy in cancer. The potential of TLR3-Ligands such as APOXXIM® to treat cancer has been extensively studied in the past decades by scientists at TOLLYS, with a particular focus on TLR3-positive cancers."